Rifer. bibliografici : Anticancer properties of polysaccharides isolated from fungi of the Basidiomycetes class. Lemieszek M, Rzeski W. Contemp Oncol (Pozn). 2012;16(4):285-9. doi: 10.5114/wo.2012.30055. Epub 2012 Sep 29 (81 titoli)

  1. Mushroom nutriceuticals. Chang ST, Buswell JA. World J Microb Biotech. 1996;12:473–6. [PubMed]

  2. Medicinal Mushrooms: An Exploration of Tradition, Healing and Culture. Hobbs CH. Botanica Press: Williams, OR; 1995.

  3. Związki biologicznie aktywne zawarte w grzybach jadalnych i ich korzystny wpływ na zdrowie. Rajewska J, Bałasińska B. Postępy Hig Med Dosw. 2004;58:352–7. [PubMed]

  4. Medicinal properties of substances occurring in higher Basidiomycetes. Wasser SP, Weis AL.  Int J Med Mushr. 1999;1:31–62.

  5. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Wasser SP, Weis AL. Critical Rev Immunol. 1999;19:65–96.[PubMed]

  6. Tumor inhibitors in Boletus edulis and other holobasidiomycetes. Lucas EH, Montesano R, Pepper MS, Hafner M, Sablon E.  Antibiot Chemother. 1957;7:1–4.

  7. Production of oncostatic principles in vivo and in vitro by species of the genus Calvatia.  Lucas EH, Byerrum M, Clarke DA, Reilly HC, Stevens JA, Stock CC. Antibiot Annu.1958;6:493–6. [PubMed]

  8. Development of antitumor polysaccharides from mushroom fungi. Mizuno T. Foods Food Ingred J Jpn. 1996;167:69–85.

  9. The extraction and development of antitumoractive polysaccharides from medicinal mushrooms in Japan. Mizuno T.  Int J Med Mushrooms. 1999;1:9–29.

  10. Bioactive substances in Hericium erinaceus (Bull. Fr.) Pers. (Yamabushitake), and its medicinal utilization. Mizuno T. Int J Med Mushrooms. 1999;1:105–19.

  11. Higher Basidiomycota as a source of antitumor and immunostimulating polysaccharides. Reshetnikov SV, Wasser SP, Tan KK.  Int J Med Mushrooms. 2001;3:361–94.

  12. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Wasser SP. Appl Microbiol Biotechnol. 2002;60:258–74. [PubMed]

  13. Yamabushitake, Hericium erinaceum: bioactive substances and medicinal utilization. Mizuno T.  Food Rev Intern. 1995;11:173–8.

  14. The chemistry of polysaccharides of fungi and lichens. Gorin PAJ, Barreto-Berger E.  In: Aspinall GO, editor. W: The polysaccharides. Academic Press: Orlando; 1983. pp. 365–409.

  15. Glucans as modulating polysaccharides:thei characteristics and isolation from microbiological sources. Augustin J. Biologia. 1998;53:277–82.

  16. Bao X, Duan J, Fang X, Fang J. Chemical modifications of the (13)-α-D-glucan from spores of Ganoderma lucidum and investigation of their physicochemical properties and immunological activity. Carbohydrate Res. 2001;336:127–40. [PubMed]

  17. Physicochemical properties and antitumor activities of watersoluble native and sulfated hyperbranched mushroom polysaccharides. Tao Y, Zhang L, Cheung PCK. Carbohydrate Res. 2006;341:2261–9. [PubMed]

  18. Evaluation of sulfated Lentinus edodes α-(1,3)-D-glukan as a potential antitumor agent. Zhang P, Cheung PCK. Biosci Biotechnol. Biochem. 2002;66:1052–6. [PubMed]

  19. Anti-tumoractive substances from mushrooms. Mizuno T, Saito H, Nishitoba T, Kawagishi H. Food Rev Int. 1995;11:23–61.

  20. Gao QP, Seljelid R, Chen HQ, Jiang R. Characterization of acidic heteroglycans from Tremella fuciformis Berk. with cytokine stimulating activity. Carbohydr Res.1996;288:135–42. [PubMed]

  21. Kawagishi H, Kanao T, Inagaki R, Mizuno T, Shimura K, Ito H, Hagiwara T, Hakamura T. Formulation of a potent antitumor (16)-beta-D-glucan-protein complex from Agaricus blazei fruiting bodies and antitumor activity of the resulting products.Carbohydr Polym. 1990;12:393–404.

  22. Zhuang C, Mizuno T, Shimada A, et al. Antitumor protein-containing polysaccharides from a Chinese mushroom Fengweigu or Houbitake, Pleurotus sajor-caju (Fr.) Sing. Biosci Biotechnol Biochem. 1993;57:901–6. [PubMed]

  23. Mizuno T, Yeohlui P, Kinoshita T, Zhuang C, Ito H, Mayuzumi Y. Antitumor activity and chemical modification of polysaccharides from Niohshimeji mushroom, Tricholoma giganteum. Biosci Biotechnol Biochem. 1996;60:30–3. [PubMed]

  24. Manzi P, Pizzoferrato L. Beta-glucans in edible mushrooms. Food Chem.2000;68:315–8.

  25. Maeda YY, Watanabe ST, Chihara C, Rokutanda M. Denaturation and renaturation of a β-1,6; 1,3-glucan, lentinan, associated with expression of T-cell-mediated responses.Cancer Res. 1988;48:671–5. [PubMed]

  26. Yanaki T, Ito W, Tabata K, Kojima T, Norizuye T, Takano N, Fujita H. Correlation between the antitumor activity of a polysaccharide schizophyllan and its triple-helical conformation in dilute aqueous solution. Biophys Chem. 1983;17:337–42. [PubMed]

  27. Yanaki T, Ito W, Tabata K. Correlation between antitumor activity of schizophyllan and its triple helix. Agric Biol Chem. 1986;509:2415–6.

  28. Ooi VEC, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000;7:715–729. [PubMed]

  29. Zhang M, Cui SW, Cheung PCK, Wang Q. Antitumor polysaccharides from mushrooms: a review on their isolation process, structural characteristics and antitumor activity. Trends in Food Sci Technol. 2007;18:4–19.

  30. Karácsonyi S, Kuniak L. Polysaccharides of Pleurotus ostreatus: isolation and structure of pleuran, an alkali-insoluble β-D-glucan. Carbohydr Polym. 1994;24:107–11.

  31. Kuniak L, Karácsonyi S, Augusti J, Ginterová A, Széchényl S, Kravarik D, Dubaj J, Varjú J. A new fungal glucan and its preparation; World Patent 9312243; Date of Patent 24.06.1993.

  32. Paulik S, Svrcec, Mojisová J, Durove A, Benisek Z, Húska M. The immunomodulatory effect of the soluble fungal glucan (Pleurotus ostreatus) on delayed hypersensitivity and phagocytic ability of blood leucocytes in mice. J Vet Med B. 1996;43:129–35. [PubMed]

  33. Zhuang C, Mizuno T, Ito H, Shimura K, Sumiya T. Chemical modification and antitumor activity of polysaccharides from the mycelium of liquid-cultured Grifola frondosa. Nippon Shokuhin Kogyo Gakkaishi. 1994;41:733–40.

  34. Miles PG, Chang ST. Mushroom biology. Concise basics and current developments; Singapore, New Jersey, London, Hong Kong: World Scientific; 1997. p. 194.

  35. Mahajna JA, Yassin M, Wasser SP. Mushrooms extracts having anticancer activity; US: USA Patent; 7,258,862 B2, Date of Patent 21.08.2007.

  36. Chihara G, Maeda Y, Hamuro J, Sasaki T, Fumiko F. Inhibition of mouse Sarcoma 180 by polysaccharides from Lentinus edodes (Berk.)Sing. Nature. 1969;222:687–8.[PubMed]

  37. Chihara G, Hamuro J, Maeda YY, Arai Y, Fukuoka F. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes. Cancer Res. 1970;30:2776–81. [PubMed]

  38.  Ikekawa T, Uehara N, Maeda Y, Nakanishi M, Fukuoka F. Antitumor activity of aqueous extracts of edible mushrooms. Cancer Res. 1969;29:734–5. [PubMed]

  39. Brown G, Siamon G. Immune recognition: A new receptor for β-glucans. Nature.2001;413:36–7. [PubMed]

  40. Herre J, Gordon S, Brown GD. Dectin-1 and its role in the recognition of β-glucans by macrophages. Mol Immunol. 2004;40:869–76. [PubMed]

  41. Zhu D. Recent advances on the active components in Chinese medicines. Abstr Chin Med. 1987;1:251–86.

  42. Borchers AT, Stern JS, Hackman RM, Keen CL, Gershwin ME. Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med. 1999;221:281–93. [PubMed]

  43. Czop JK, Austen KF. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor. J Immunol. 1985;135:3388–93. [PubMed]

  44. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology. 1999;42:61–74.[PubMed]

  45. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol. 1999;162:2281–90. [PubMed]

  46. Vetvicka V, Thornton BP, Wieman TJ, Ross GD. Targeting of NK cells to mammary carcinoma via naturally occurring tumor cellbound iC3b and beta-glucan-primed CR3 (CD11b/CD18) J Immunol. 1997;159:599–605. [PubMed]

  47. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD. Beta-glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18) J Immunol.1999;163:3045–52. [PubMed]

  48. Hamuro J, Chihara G. Lentinan, a T-cell oriented immunopotentiator: its experimental and clinical applications and possibile mechanism of immune modulation. In: Fenichel RL, Chirigos MA, editors. W: Immunomodulation agents and their mechanisms. New York: Dekker; 1985. pp. 409–36.

  49. Aoki T. Lentinan. In: Femchel RL, Chirgis MA, editors. Immunology Studies: Immune modulation agents and their mechanisms. Vol. 25. 1984. pp. 62–77.

  50. Hobbs C. Medicinal value of Lentinus edodes (Berk.) Sing. (Agaricomycetideae). A literature review. International Journal of Medicinal Mushrooms. 2000;2:287–302.

  51. Chihara G, Maeda YY, Taguchi T, Hamuro J. Lentinan as a host defence potentiator (HDP) International Journal of Immunotherapy. 1989;5:145.

  52. Chihara G. Immunopharmacology of Lentinan, a polysaccharide isolated from Lentinus edodes: its application as a host defense potentiator. International Journal Oriental Medicine. 1992;17:57–77.

  53. Wang GL, Lin ZB. The immunomodulatory effect of lentinan. Yao Xue Xue Bao.1996;31:86–90. [PubMed]

  54. Lull C, Wichers HJ, Savelkoul HFJ. Antiinflamatory and immunomodulating properties of fungal metabolites. Mediators of inflammation. 2005;2:63–80.[PMC free article] [PubMed]

  55. Hamuro J. Anticancer immunotherapy with perorally effective lentinan. Gan To Kagaku Ryoho. 2005;32:1209–15. [PubMed]

  56. Kerekgyarto C, Virag L, Tanko L, Chihara G, Fachet J. Strain differences in the cytotoxic activity and TNF production of murine macrophages stimulated by lentinan. Int J Immunopharmacol. 1996;18:347–53. [PubMed]

  57. Takada K, Okumara K. CAM and NK cells. eCAM. 2004;1:17–27. [PMC free article][PubMed]

  58. Suga T, Maeda YY, Uchida H, Rokutanda M, Chihara G. Macrophage-mediated acute-phase transport protein production induced by Lentinan. International Journal of Immunopharmacology. 1986;8:691. [PubMed]

  59. Tzianabos A. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clinical Microbiology Reviews. 2000;13:523–33.[PMC free article] [PubMed]

  60. Mizutani Y, Yoshida O. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer. J Urol.1991;145:1082–7. [PubMed]

  61. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Imai S, Tobe T. In vitro immunomodulating effect of protein-bound polysaccharide PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Imunol Immunother. 1991;32:335–41. [PubMed]

  62. Hsieh TC, Wu JM. Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells. Int J Oncol. 2001;18:81–8. [PubMed]

  63. Kato M, Hirose K, Hakozak M, et al. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother. 1995;40:152–6. [PubMed]

  64. Liu F, Fang MC, Ooi VEC, Chang ST. Induction in the mouse of gene expression of immunomodulating cytokines by mushroom polysaccharide-protein complexes. Life Science. 1996;58:1795–803. [PubMed]

  65. Sakagami H, Sugaya K, Utsumi A, Fujinaga S, Sato T, Takeda M. Stimulation by PSK of interleukin-1 production by human peripheral blood mononuclear cells. Anticancer Res.1993;13:671–5. [PubMed]

  66. Okazaki M, Adach Y, Ohno N, Yadomae T. Structure-activity relationship of (1-3)-β-Dglucan in the induction of cytokine production from macrophages in vitro. Biological Pharmacological Bulletin. 1995;18:1320–7. [PubMed]

  67. Kraus J, Franz G. β(1-3) Glucans: anti-tumour activity and immunostimulation. In: Latge JP, Boucias D, editors. W: Fungal Wall and Immune Response. Berlin: NATO ASI Series H53, Springer; 1991. pp. 39–42.

  68. Kraus J, Franz G. Immunomodulating effects of polysaccharides from medicinal plants. In: Friedman H, Klein TW, Yamaguchi H, editors. W: Microbial Infections.NewYork: Plenum Press; 1992. pp. 299–308.

  69. Bohn JA, BeMiller JN. (1-3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydrate Polymers. 1995;28:3–14.

  70. Falch BH, Espevik T, Ryan L, Stokke BT. The cytokine stimulating activity of (13)-beta-Dglucans is dependent on the triple helix formation. Carbohydr Res. 2000;329:587–96. [PubMed]

  71. Kubala J, Ruzickova J, Nickova K, Sandula J, Ciz M, Lojek A. The effect of (13)-beta-D-glucans, carboxymethyloglucan and schizophyllan on human leukocytes in vitro.Carbohydr Res. 2003;338:2835–40. [PubMed]

  72. Smith JE, Rowan NJ, Sullivan R. Medicinal mushrooms: a rapidly developing area of biotechnology for cancer therapy and other bioactivities. Biotech Letters. 2002;24:1839–45.

  73. Ravi R, Bedi A. NF-kappa B in cancer-a friend turned foe. Drug Resist Update.2004;7:53–67. [PubMed]

  74. Ohno N, Miura NN, Nakajima M, Yadomae T. Anti-tumor 1,3-β-glucan from cultured fruit body of Sparassis crispa. Biol Pharm Bull. 2000;23:866–872. [PubMed]

  75. Ohno N, Nameda S, Harada T, et al. Immunomodulating activity of a ß-glucan preparation, SCG, extracted from a culinary-medicinal mushroom, Sparassis crispa Wulf.: Fr. (Aphyllophoromycetidae), and application to cancer patients. Int J Med Mushr.2003;5:359–68.

  76. Yoshida I, Kiho T, Usui S, Sakushima M, Ukai S. Polysaccharides in fungi. XXXVII. Immunomodulating activities of carboxymethylated derivatives of linear (1-3)-alpha-d-glucans extracted from the fruiting bodies of Agrocybe cylindracea and Amanita muscaria.Biol Pharm Bull. 1996;19:114–21. [PubMed]

  77. Yoshioka Y, Ikekawa T, Noda M, Fukuoka F. Studies on anti-tumor activity of some fractions from Basidiomycetes. I. An anti-tumor acidic polysaccharide fraction of P. ostreatus (Fr.) Quél. Chem Pharm Bull. 1972;20:1175–80. [PubMed]

  78. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-κB and cancer. Clin Oncol (R Coll Radiol)2007;19:154–61. [PubMed]

  79. Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle. 2003;2:550–2. [PubMed]

  80. Chow LW, Lo CS, Loo WT, Hu XC, Sham JS. Polysaccharide peptide mediates apoptosis by up-regulating p21 gene and downregulating cyclin D1 gene. Am J Chin Med.2003;31:1–9. [PubMed]

  81. Hsieh T, Wu P, Park S, Wu JM. Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-YunityTM (PSP) BMC Complement Altern Med. 2006;6:30.[PMC free article] [PubMed]